Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21211528 | 0.87 | TDP1 (0.70) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL5590271 | 0.81 | MAPT (0.68) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL11117408 | 0.81 | MAPT (0.68) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL29670844 | 0.81 | MAPT (0.68) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL138261 | 0.79 | SMN1; SMN2 (0.83) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL24337026 | 0.79 | L3MBTL1 (0.62) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL18211842 | 0.79 | NPSR1 (0.63) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL8179855 | 0.79 | TDP1 (0.59) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL18211844 | 0.78 | TDP1 (0.63) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 | |
| SCHEMBL1548457 | 0.78 | KDM4E (0.55) | TDP1MAPTSMN1; SMN2LIN28ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| EP-2314609-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | claimed |
| JP-4653840-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| JP-2009520682-A | — | — | 2009-05-28 | — | — | JP | claimed |
| US-20090105152-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | claimed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | claimed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | claimed |
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-8404643-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-7960348-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | disclosed |
| EP-1581557-A2 | METASTIN DERIVATIVES AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-6800611-B2 | ANTICANCER AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| WO-2004060264-A2 | METASTIN DERIVATIVES AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040142875-A1 | \"metastin\" is the ligand to a G-protein-coupled orphan receptor known as OT7T175 or AXOR12; prodrug; treating cancer, hydatid mole, invasive mole, miscarriage, fetal hypoplasia, sugar dysbolism, lipid dysbolism or labor induction in a mammal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | KLK3, SHBG, SERPINA3 | TDP1 3063/4885MAPT 3788/4885SMN1; SMN2 3156/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | TDP1 4722/4885MAPT 3419/4885SMN1; SMN2 3461/4885 |
| US-20040142875-A1 | \"metastin\" is the ligand to a G-protein-coupled orphan receptor known as OT7T175 or AXOR12; prodrug; treating cancer, hydatid mole, invasive mole, miscarriage, fetal hypoplasia, sugar dysbolism, lipid dysbolism or labor induction in a mammal | GPR27, GPR132, LPAR3 | TDP1 4610/4885MAPT 4166/4885SMN1; SMN2 3702/4885 |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | TDP1 4718/4885MAPT 4178/4885SMN1; SMN2 2775/4885 |
| US-20090105152-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | TDP1 4718/4885MAPT 4178/4885SMN1; SMN2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.